|
|
|
VGX Pharmaceuticals
Announces Issuance of Two Key U.S. Patents
Covering DNA Plasmid Manufacturing Technology and the Treatment
of Anemia
|
| Blue
Bell, PA – July 11, 2007 – |
|
VGX Pharmaceuticals today announced that it has been
granted U.S. Patent number 7,238,522 covering its DNA plasmid manufacturing
technology. The patent entitled, "Device and Methods for Biomaterial
Production" represents the first to issue of a series of applications
related to VGX's novel approach to DNA plasmid manufacturing.
"We are very pleased to have been granted this patent as it further
differentiates our proprietary plasmid manufacturing and recovery process,"
stated Dr. J. Joseph Kim, President and CEO of VGX. "We believe that
VGX’s patented lysis and harvest process offers an efficient and
cost-effective technology for producing DNA plasmids, particularly at
large scale where conventional approaches are inefficient or just not
feasible.”
VGX has established a flexible, purpose-built cGMP facility used for research,
development, and clinical supply at its Texas manufacturing site. In addition
to manufacturing DNA plasmids for its own product development needs, VGX
offers contract manufacturing services to outside client organizations.
The cGMP facility has passed rigorous reviews by several regulatory agencies
worldwide.
The second patent, US 7,241,744 covers methods and approaches to treat
anemia. The patent entitled, “Treating Anemia in Subjects by Administration
of Plasmids Encoding Growth Hormone Releasing Hormone (GHRH)” is
part of a broad patent estate covering GHRH sequences and applications.
VGX is presently developing the GHRH technology in the areas of cancer
cachexia and anemia, and the first clinical studies are planned for early
2008.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About VGX
Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company with small molecules
and biologics product candidates for the treatment of infectious diseases,
cancer and inflammatory diseases. The Company's clinical development programs
include PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection,
both of which are currently in Phase II clinical trials. In addition, VGX
is planning to initiate Phase I clinical studies for VGX-1027, its lead
compound for inflammatory diseases. VGX's research pipelines include new
generation of DNA vaccines and therapeutics as well as CELLECTRA™,
a proprietary DNA delivery device. The product candidates and technology
programs are protected by the Company's extensive global intellectual property
portfolio. More information about VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
